levonorgestrel has been researched along with naproxen in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Allsworth, JE; Madden, T; Peipert, JF; Proehl, S; Secura, GM | 1 |
| Bofill Rodriguez, M; Brown, J; Lethaby, A; Weterings, MA; Wise, MR | 1 |
| Bongers, MY; Bui, BN; Bullens, LM; Delvaux, EJLG; Geomini, PMAJ; Tibosch, RMG; van der Heijden, PAHH; Veersema, S | 1 |
| Baêta, T; Brant, APC; de Oliveira, ECF; Rocha, ALL; Silva-Filho, A | 1 |
3 review(s) available for levonorgestrel and naproxen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combined hormonal contraceptives for heavy menstrual bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Danazol; Drug Therapy, Combination; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Mefenamic Acid; Menorrhagia; Naproxen; Nausea; Placebos; Progestins; Randomized Controlled Trials as Topic | 2019 |
What is the best drug treatment for premenopausal women with bleeding irregularities using the levonorgestrel-releasing intrauterine system? A systematic review.
Topics: Contraceptive Agents, Hormonal; Cyclooxygenase Inhibitors; Estradiol; Estrogens; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Menorrhagia; Naproxen; Premenopause | 2020 |
2 trial(s) available for levonorgestrel and naproxen
| Article | Year |
|---|---|
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Estradiol; Estrogens; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Metrorrhagia; Naproxen; Treatment Outcome | 2012 |
Use of naproxen versus intracervical block for pain control during the 52-mg levonorgestrel-releasing intrauterine system insertion in young women: a multivariate analysis of a randomized controlled trial.
Topics: Contraceptive Agents, Female; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Multivariate Analysis; Naproxen; Pain | 2021 |
3 other study(ies) available for levonorgestrel and naproxen
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |